Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Lisa Salvatore(University of Pisa), Vittorina Zagonel(Istituto Oncologico Veneto), C. Boni(Ospedale Santa Maria), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Sara Lonardi(Istituto Oncologico Veneto), Rosella Spadi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Gianluca Masi(University of Pisa), Angela Buonadonna(Centro di Riferimento Oncologico), Giuseppe Tonini(Campus Bio Medico University Hospital), Chiara Carlomagno(Federico II University Hospital), Luca Boni(Ospedale Policlinico San Martino), Chiara Cremolini(University of Pisa), Giacomo Allegrini, D. Amoroso(Ospedale Versilia), Enrico Cortesi(Sapienza University of Rome), Gianluca Tomasello(Istituti Ospitalieri di Cremona), Silvana Chiara(Ospedale Policlinico San Martino), Monica Ronzoni
Cited by 1,078
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k